ライフサイエンスコーパス: epidermal growth factor-like

1 ctrophotometric analysis revealed that nerve epidermal growth factor-like 1 (NELL1) immune complexes

2 Neural epidermal growth factor-like 1 (NELL1) is the second lea

3 describe four biopsy-proven cases of neural epidermal growth factor-like 1 (NELL1)-associated membra

4 NELL1 and NELL2 (neural epidermal growth factor-like 1 and 2) are recently descr

5 ug-induced membranous nephropathy are neural epidermal growth factor-like 1 and proprotein convertase

6 ajor cause of nephrotic syndrome, and neural epidermal growth factor-like 1 protein (NELL1) is the se

7 ociated with one antigen (such as for neural epidermal growth factor-like 1); ( 3 ) rare presence of

8 In this study, we identified epidermal growth factor-like 6 (Egfl6) as a regulator of

9 at the avB5 integrin ligand milk fat globule epidermal growth factor like 8 (MFGE8) regulates cellula

10 ding of the integrin ligand milk fat globule epidermal growth factor like 8 (MFGE8) to the alphavbeta

11 In this study, we demonstrate that epidermal growth factor-like 9 (EGFL9) is significantly

12 SK9) is a secreted protein that binds to the epidermal growth factor-like-A domain of the low density

13 as tomoregulin or transmembrane protein with epidermal growth factor-like and 2 follistatin-like doma

14 , epidermal growth factor-like, laminin-type epidermal growth factor-like, and link domain-containing

15 e N-terminal end, proline-rich C region, and epidermal growth factor-like calcium-binding (EGF-cb) do

16 o repeated module types: the calcium binding epidermal growth factor-like (cbEGF) domain and the tran

17 We have used recombinant calcium binding epidermal growth factor-like (cbEGF) domain fragments fr

18 rganisation that includes 43 calcium binding epidermal growth factor-like (cbEGF) domains and seven t

19 rganisation that includes 43 calcium-binding epidermal growth factor-like (cbEGF) domains arranged as

20 dominantly composed of eight calcium-binding epidermal growth factor-like (cbEGF) domains, each of wh

21 The calcium-binding epidermal growth factor-like (cbEGF) module and the tran

22 conformation of fibrillin-1 calcium-binding epidermal growth factor-like (cbEGF-like) domains within

23 with subsequent release of its extracellular epidermal growth factor-like-containing domain and autoc

24 cysteine-rich domain instead of the expected epidermal growth factor-like disulfide structure.

25 FVII with an in-frame deletion of the first epidermal growth factor-like domain (EGF 1).

26 The first epidermal growth factor-like domain (EGF-1) from blood c

27 The functional importance of the N-terminal epidermal growth factor-like domain (EGF-N) of factor X/

28 rombin-sensitive region (TSR), and the first epidermal growth factor-like domain (EGF1) of protein S,

29 polypeptides in which residues in the third epidermal growth factor-like domain (EGF3) are mutated d

30 f conserved aspartate/asparagine residues in epidermal growth factor-like domain (EGFD) proteins.

31 g the single transmembrane receptor multiple epidermal growth factor-like domain 10 (MEGF10) cause an

32 Aim of this study was to assess whether Epidermal Growth Factor-Like domain 7 (EGFL7) dosage in

33 Epidermal growth factor-like domain 7 (Egfl7) is importa

34 this method, we developed an assay for human epidermal growth factor-like domain 7 (EGFL7), an extrac

35 cally, we show that CASZ1 directly regulates Epidermal Growth Factor-Like Domain 7 (Egfl7).

36 ammalian uPA by lacking two cysteines of the epidermal growth factor-like domain and a uPAR-binding s

37 ctor VIII allows the factor IXa protease and epidermal growth factor-like domain binding sites (local

38 2 (HER2) receptor tyrosine kinase through an epidermal growth factor-like domain in its extracellular

39 Neuregulins contain an epidermal growth factor-like domain located C-terminally

40 We have cloned, expressed, and purified the epidermal growth factor-like domain of murine uPA alone

41 oneoplastic potential in comparison with the epidermal growth factor-like domain of neuregulin-1beta

42 amino-acid residue within the fifth laminin-epidermal growth factor-like domain of the USH2A gene an

43 ats 1-2 and 6-8 of tenascin-R but not to the epidermal growth factor-like domain or the fibrinogen-li

44 mmation, but the function of the recombinant epidermal growth factor-like domain plus serine/threonin

45 a chimeric Factor IX by replacing the first epidermal growth factor-like domain with that of Factor

46 motif, (iii) a cysteine-rich domain, (iv) an epidermal growth factor-like domain, (v) a hydrophobic t

47 Upon deletion of its C-terminal epidermal growth factor-like domain, BAD-1 resisted aggr

48 arginine at a highly conserved residue of an epidermal growth factor-like domain, impairs Wnt signali

49 Deletion of the C-terminal epidermal growth factor-like domain, in which Asn(350) i

50 ipocyte factor-1 (Pref-1) is a transmembrane epidermal growth factor-like domain-containing protein h

51 Pref-1 is an epidermal growth factor-like domain-containing transmemb

52 e region that is N-terminal of the bioactive epidermal growth factor-like domain.

53 N-terminal fragment containing the bioactive epidermal growth factor-like domain.

54 y lacking the exon encoding the uPAR-binding epidermal growth factor-like domain; zfuPA-b differs fro

55 alloendopeptidase isolated from crayfish, an epidermal growth-factor-like domain, and three regions o

56 /kexin type 9 (PCSK9) through the first EGF (epidermal growth factor-like) domain [EGF(A)].

57 Epidermal Growth Factor Like-domain 7 (EGFL7), firstly d

58 Calcium binding epidermal growth factor-like domains (cbEGFs) are presen

59 Epidermal growth factor-like domains (EGFDs) have import

60 ses the hydroxylation of Asp/Asn-residues in epidermal growth factor-like domains (EGFDs).

61 ylations of aspartate/asparagine residues of epidermal growth factor-like domains (EGFDs).

62 nal hydroxylation of Asp and Asn residues in epidermal growth factor-like domains (EGFDs).

63 ion of asparaginyl- and aspartyl-residues in epidermal growth factor-like domains (EGFDs).

64 E1 (tyrosine kinase with immunoglobulin- and epidermal growth factor-like domains 1) missense variant

65 Epidermal growth factor-like domains 1-4 comprise the co

66 y demonstrated that upregulation of multiple epidermal growth factor-like domains 11 (MEGF11) gene ex

67 egion of fibrillin-1 between calcium-binding epidermal growth factor-like domains 11 and 21.

68 ne-rich tandem repeats encompassing integrin-epidermal growth factor-like domains 2, 3, and 4 of the

69 ntiation-related protein, cysteine-rich with epidermal growth factor-like domains 2, nuclear protein

70 for CD47 in Mac-1 were localized in integrin epidermal growth factor-like domains 3 and 4 of the beta

71 al structure of thrombin in complex with the epidermal growth factor-like domains 4, 5, and 6 of TM (

72 The epidermal growth factor-like domains 4-6 of thrombomodul

73 vation of alpha-thrombin in complex with the epidermal growth factor-like domains 4-6 of TM (TM4-6) w

74 Thrombomodulin (TM), or its epidermal growth factor-like domains 456 (TM456), enhanc

75 in, suggesting that this region contains the epidermal growth factor-like domains 5 and 6.

76 d specifically with ErbB2 through one of its epidermal growth factor-like domains and that the co-exp

77 d soluble EMR2, containing highly homologous epidermal growth factor-like domains but a different sta

78 Notch is modified in its epidermal growth factor-like domains by the addition of

79 portions encompassing the N-terminal CUB and epidermal growth factor-like domains have been expressed

80 a highly conserved enzyme that hydroxylates epidermal growth factor-like domains in transformation-a

81 atistically significant sequence homology to epidermal growth factor-like domains is found, and a dis

82 plex with a naphthyl inhibitor DX-9065a, two epidermal growth factor-like domains of factor Xa are we

83 to position 274 is highly conserved in other epidermal growth factor-like domains of jagged1 and in t

84 erase 1 (OFUT1), an enzyme that glycosylates epidermal growth factor-like domains of Notch, also has

85 e residues at a strict consensus site within epidermal growth factor-like domains of several serum pr

86 n variants of tenascin-C containing only the epidermal growth factor-like domains or the fibronectin

87 In contrast, no binding was observed to the epidermal growth factor-like domains or to the activatio

88 The structure reveals two tightly packed epidermal growth factor-like domains oriented head to ta

89 181 aa long N-terminal domain containing two epidermal growth factor-like domains, a follistatin moti

90 gamma-carboxyglutamic acid (Gla) domain, two epidermal growth factor-like domains, and a protease dom

91 d stronger blocking compared with mAb to its epidermal growth factor-like domains, and binding was ca

92 The latter, which contains two epidermal growth factor-like domains, binds the receptor

93 domains of BMP1 and mTLL1, devoid of CUB or epidermal growth factor-like domains, have procollagen C

94 ve activity and a transmembrane subunit with epidermal growth factor-like domains, one of which acts

95 ith human fibrillin-2 and had Ca(2+) binding epidermal growth factor-like domains, transforming growt

96 few helical hydrophobic residues and the two epidermal growth factor-like domains, whereas the heavy

97 ne-binding globulin, with three interspersed epidermal growth factor-like domains.

98 ed conformation of the N-terminal lectin and epidermal growth factor-like domains.

99 ormed by the disintegrin, cysteine-rich, and epidermal growth factor-like domains.

100 samine in a beta1,3 linkage onto O-fucose on epidermal growth factor-like domains.

101 e a disorder caused by mutations in multiple epidermal-growth-factor-like-domains 8 (MEGF8), which ex

102 , C6PS binds to two sites on FXa, one in the epidermal growth factor-like (EGF) domain and one in the

103 Epidermal growth factor-like (EGF) domain Ca2+ binding s

104 sists of 11 exons with an Ig-like domain, an epidermal growth factor-like (EGF) domain, a beta-stalk,

105 O-Linked fucose modifications on Notch1 epidermal growth factor-like (EGF) domains 8 and 12 enga

106 Calcium binding (cb) epidermal growth factor-like (EGF) domains are found in

107 ual forms of O-linked glycosylation found on epidermal growth factor-like (EGF) modules.

108 des a secreted molecule containing a variant epidermal growth factor-like (EGF) motif.

109 s studies suggest that O-fucosylation of the epidermal growth factor-like (EGF) repeat in Cripto is e

110 is an unusual form of glycosylation found on epidermal growth factor-like (EGF) repeats and thrombosp

111 Epidermal growth factor-like (EGF) repeats are also smal

112 st-translational modification that occurs on epidermal growth factor-like (EGF) repeats harboring the

113 O-Glucosylation of epidermal growth factor-like (EGF) repeats in the extrac

114 y protein O-fucosyltransferase 1 (POFUT1) to epidermal growth factor-like (EGF) repeats in the NOTCH1

115 Notch receptors contain multiple epidermal growth factor-like (EGF) repeats modified by O

116 Mutations within the 47 epidermal growth factor-like (EGF) repeats of FBN1 cause

117 O-Fucose has been identified on epidermal growth factor-like (EGF) repeats of Notch, and

118 erase that modifies O-fucose moieties on the epidermal growth factor-like (EGF) repeats of Notch.

119 h activity by modifying O-fucose residues on epidermal growth factor-like (EGF) repeats of Notch.

120 receptors require modification by fucose on epidermal growth factor-like (EGF) repeats of their extr

121 ar domain of mouse Notch1 contains 36 tandem epidermal growth factor-like (EGF) repeats, many of whic

122 FBN1 contains 47 epidermal growth factor-like (EGF) repeats, which are pr

123 hway and transfers O-GlcNAc to proteins with epidermal growth factor-like (EGF) repeats.

124 ase that modifies O-fucose in the context of epidermal growth factor-like (EGF) repeats.

125 comprises multiple copies of ligand binding, epidermal growth factor-like (EGF), and YWTD-type domain

126 Ca2+ binding epidermal growth factor-like (EGF-like) domains are foun

127 The receptor also contains 7 epidermal growth factor-like (Egf-like) motifs at the am

128 nning activity was also inhibited by another epidermal growth factor-like (EGF-like) peptide, neuregu

129 DASIL mutations described to date affect the epidermal growth factor-like (EGF-like) repeats located

130 uregulins (NRGs) are a family of multipotent epidermal-growth-factor-like (EGF-like) factors that ari

131 We previously reported that the first epidermal growth factor-like (EGF1) domain in factor X (

132 We investigated factor VIIa's first epidermal growth factor-like (egf1) domain's role in the

133 vulation by regulating the expression of the epidermal growth factor-like family of growth factors.

134 ransmembrane receptor member of the homeotic epidermal growth factor-like family of proteins, partici

135 Heparin-binding epidermal growth factor -like growth factor (HB-EGF) exp

136 selectivity of ADAM17 toward Heparin-binding epidermal growth factor like growth factor (HB-EGF), a c

137 pport a critical role for heparin-bound EGF (epidermal growth factor)-like growth factor (HB-EGF) and

138 the increased expression of heparin-binding epidermal growth factor-like growth factor (EGFR ligand)

139 Furthermore, heparin-binding epidermal growth factor-like growth factor (HB- EGF), a

140 n the ectodomain cleavage of heparin-binding epidermal growth factor-like growth factor (HB-EGF) and

141 ite can activate cleavage of heparin-binding epidermal growth factor-like growth factor (HB-EGF) and

142 rray analysis and identified heparin-binding epidermal growth factor-like growth factor (HB-EGF) as b

143 We identify heparin binding epidermal growth factor-like growth factor (HB-EGF) as t

144 wth factor was identified as heparin-binding epidermal growth factor-like growth factor (HB-EGF) base

145 growth factor-2 (FGF-2) and heparin-binding epidermal growth factor-like growth factor (HB-EGF) bind

146 igated the effect of VEGF on heparin-binding epidermal growth factor-like growth factor (HB-EGF) expr

147 Heparin-binding epidermal growth factor-like growth factor (HB-EGF) has

148 Heparin-binding epidermal growth factor-like growth factor (HB-EGF) has

149 Heparin-binding epidermal growth factor-like growth factor (HB-EGF) is a

150 Heparin binding epidermal growth factor-like growth factor (HB-EGF) is a

151 Heparin-binding epidermal growth factor-like growth factor (HB-EGF) is a

152 Heparin-binding epidermal growth factor-like growth factor (HB-EGF) is a

153 Heparin-binding epidermal growth factor-like growth factor (HB-EGF) is a

154 Heparin-binding epidermal growth factor-like growth factor (HB-EGF) is a

155 Heparin-binding epidermal growth factor-like growth factor (HB-EGF) is a

156 Heparin-binding epidermal growth factor-like growth factor (HB-EGF) is e

157 Heparin-binding epidermal growth factor-like growth factor (HB-EGF) is p

158 Heparin-binding epidermal growth factor-like growth factor (HB-EGF) is s

159 have recently reported that heparin-binding epidermal growth factor-like growth factor (HB-EGF) mRNA

160 tomy mice, the expression of heparin-binding epidermal growth factor-like growth factor (HB-EGF) prec

161 phtheria toxin (DT) receptor/heparin-binding epidermal growth factor-like growth factor (HB-EGF) prec

162 We have shown that heparin-binding epidermal growth factor-like growth factor (HB-EGF) prot

163 Heparin-binding epidermal growth factor-like growth factor (HB-EGF), a m

164 Heparin-binding epidermal growth factor-like growth factor (HB-EGF), a m

165 Heparin-binding epidermal growth factor-like growth factor (HB-EGF), a m

166 s study, we demonstrate that heparin-binding epidermal growth factor-like growth factor (HB-EGF), a p

167 cacy of locally administered heparin-binding epidermal growth factor-like growth factor (HB-EGF), a p

168 We examined whether, heparin binding-epidermal growth factor-like growth factor (HB-EGF), a r

169 Heparin-binding epidermal growth factor-like growth factor (HB-EGF), an

170 The expression of heparin-binding epidermal growth factor-like growth factor (HB-EGF), an

171 duction of the growth factor heparin-binding epidermal growth factor-like growth factor (HB-EGF), are

172 that block signaling by the heparin-binding epidermal growth factor-like growth factor (HB-EGF).

173 d v-Jun target, a homolog of heparin-binding epidermal growth factor-like growth factor (HB-EGF).

174 C3s are a dominant source of heparin-binding epidermal growth factor-like growth factor (HB-EGF).

175 Here we identify heparin-binding epidermal growth factor-like growth factor (HBEGF) as a

176 recursor of the monkey (Mk) heparin-binding, epidermal growth factor-like growth factor (proHB-EGF) f

177 arin-binding growth factors, heparin-binding epidermal growth factor-like growth factor and fibroblas

178 ibroblast growth factor-2 or heparin-binding epidermal growth factor-like growth factor increases neu

179 ly, in the remodeling phase, heparin-binding epidermal growth factor-like growth factor limits mesenc

180 Heparin-binding epidermal growth factor-like growth factor promotes neur

181 ouse gene (mHB-EGF) encoding heparin-binding epidermal growth factor-like growth factor was isolated

182 eceptor (EGFR) ligand HBEGF (heparin-binding epidermal growth factor-like growth factor) and a consti

183 the ADAM17 substrate HB-EGF (heparin-binding epidermal growth factor-like growth factor).

184 An epidermal growth factor-like growth factor, amphiregulin

185 factor-alpha, amphiregulin, heparin-binding epidermal growth factor-like growth factor, and sonic he

186 forming growth factor alpha, heparin-binding epidermal growth factor-like growth factor, and Tie-2.

187 d transcripts (amphiregulin, heparin-binding epidermal growth factor-like growth factor, and transfor

188 mphiregulin and its homolog, heparin-binding epidermal growth factor-like growth factor, to the recep

189 ation of membrane content of heparin binding-epidermal growth factor-like growth factor, which serves

190 ng to the putative receptor, heparin-binding epidermal growth factor-like growth factor.

191 he heparin-binding domain of heparin-binding epidermal growth factor-like growth factor.

192 ese studies demonstrate that LH induction of epidermal growth factor-like growth factors and EGFR tra

193 Betacellulin belongs to the family of epidermal growth factor-like growth factors that are exp

194 Heparin-binding epidermal-growth-factor-like growth factor (HB-EGF) has

195 e receptor, the precursor of heparin-binding epidermal-growth-factor-like growth factor (HBEGF).

196 a transmembrane and secreted protein in the epidermal growth factor-like homeotic family.

197 the alpha subunit genu and between integrin epidermal growth factor-like (I-EGF) domains 1 and 2.

198 w density lipoprotein receptor 1; fasciclin, epidermal growth factor-like, laminin-type epidermal gro

199 rminal (LN) domain followed by three laminin epidermal growth factor-like (LE) domains and a C' regio

200 propeller domain in nidogen bound to laminin epidermal-growth-factor-like (LE) modules III3-5 in lami

201 domain followed by a tandem of laminin-type epidermal growth factor-like (LEa) domains.

202 or the first time that signaling through the epidermal growth factor-like ligand LIN-3 and the LET-23

203 not through the release of an extracellular epidermal growth factor-like ligand.

204 (SFKs), which induce proteolytic shedding of epidermal growth factor-like ligands from the cell surfa

205 y identified a secreted glycoprotein, neural epidermal growth factor-like like 2 (NELL2), in a subtra

206 epidermal growth factor-like protein, neural epidermal growth factor-like-like 2 (NELL2), specificall

207 e identified a secreted Robo3 ligand, neural epidermal growth factor-like-like 2 (NELL2), which repel

208 the extracellular glycoprotein Nell2 (neural epidermal growth factor-like-like 2) is expressed in the

209 binding repeats alone (Ca) or with the third epidermal growth factor-like module (E3Ca), without (Asn

210 ke module compared with folding of the first epidermal growth factor-like module alone.

211 sis of constructs comprised of the adjoining epidermal growth factor-like module and the Ca2+ -bindin

212 dly facilitated correct folding of the first epidermal growth factor-like module compared with foldin

213 ial of the human eosinophil surface receptor epidermal growth factor-like module containing mucin-lik

214 the thrombin-sensitive module, and the first epidermal growth factor-like module of human plasma prot

215 ow the human-restricted adhesion-GPCR, EMR2 (epidermal growth factor-like module-containing mucin-lik

216 a beta-sheet-rich protein as expected for an epidermal growth factor-like module.

217 ely cluster-of-differentiation 97 (CD97) and epidermal-growth-factor-like-module receptor 1 (EMR1)-re

218 nus of ECM1 interacted specifically with the epidermal growth factor-like modules flanking the LG2 su

219 domain of thrombospondins consists of tandem epidermal growth factor-like modules, 13 calcium-binding

220 our disulfides from a previous prediction of epidermal growth factor-like modules.

221 We have studied whether dlk, an epidermal growth factor-like molecule that intervenes in

222 n, containing two follistatin domains and an epidermal growth factor-like motif that is mainly expres

223 A common feature of proteins that include epidermal growth factor-like motifs is their involvement

224 terminal leucine-rich repeats and C-terminal epidermal growth factor-like motifs, and in Drosophila S

225 containing tandem arrays of calcium-binding epidermal growth factor-like motifs, is present in the b

226 with four additional tandem calcium-binding epidermal growth factor-like motifs.

227 their 5' ends that have some similarity with epidermal growth factor-like motifs.

228 ringe proteins and solutions from docking an epidermal growth factor-like O-fucose acceptor substrate

229 fy the endothelial cell (EC)-secreted factor epidermal growth factor-like protein 7 (EGFL7) as a nove

230 G protein-coupled CC chemokine receptor, and epidermal growth factor-like protein which are found in

231 nstrate that a testicular germ-cell-secreted epidermal growth factor-like protein, neural epidermal g

232 domain, followed by a fixed order of CUB and epidermal growth factor-like protein-protein interaction

233 hich have tertiary structures resembling the epidermal growth factor-like proteins.

234 The epidermal growth factor-like receptor tyrosine kinase (E

235 is a proto-oncogene product that encodes an epidermal growth factor-like receptor tyrosine kinase.

236 uterine pi lineage respond via their LET-23 epidermal growth factor-like receptors to a vulval-deriv

237 l injections of a small peptide encoding the epidermal growth factor-like region of heregulin ectodom

238 ur versions of recombinant C-terminal 19-kDa epidermal growth factor-like region of the major surface

239 The C-terminal 19-kDa, epidermal growth factor-like region of the merozoite sur

240 in, containing two follisatin domains and an epidermal growth factor-like region.

241 in a sequence-specific manner with the first epidermal growth factor-like repeat (EGF-A) in the EGF h

242 pairing similar to the laminin gamma1 chain epidermal growth factor-like repeat 11, suggests conform

243 receptors (LDLRs) in liver by binding to the epidermal growth factor-like repeat A (EGF-A) domain of

244 ding site of PCSK9 has been localized to the epidermal growth factor-like repeat A (EGF-A) domain of

245 ADAMTS-12 selectively binds to only the epidermal growth factor-like repeat domain of COMP of th

246 The third epidermal growth factor-like repeat dramatically altered

247 s, and 1 exon sequence had similarity to the epidermal growth factor-like repeat from several protein

248 he missplicing of exon 34, a calcium-binding epidermal growth factor-like repeat in fibrillin-2 in a

249 a Crumbs isoform that contains an additional epidermal growth factor-like repeat in the extracellular

250 The gamma chain is cleaved within the second epidermal growth factor-like repeat of domain Ill.

251 r sex, hypertension history, smoking status, epidermal growth factor-like repeat position and calenda

252 Clone H411 encodes a protein in the epidermal growth factor-like repeat protein family.

253 pref-1 is an epidermal growth factor-like repeat protein present on t

254 arated by eight YWTD spacer regions, and one epidermal growth factor-like repeat.

255 t for binding to Notch, the integrity of the epidermal-growth-factor-like repeat (ELR) 2 is also requ

256 ular domain of NOTCH1 is composed largely of epidermal growth factor-like repeats (EGFs), many of whi

257 Notch1 epidermal growth factor-like repeats 11 and 12 interact

258 an NH2-terminal Gla domain followed by four epidermal growth factor-like repeats and tandem globular

259 gside the well-established O-fucosylation of epidermal growth factor-like repeats by protein O-fucosy

260 By contrast, the region bearing epidermal growth factor-like repeats can be deleted with

261 A domain of alpha2delta-1 interacts with the epidermal growth factor-like repeats common to all throm

262 vasculature and the presence of Ca2+ binding epidermal growth factor-like repeats contained in the pr

263 rred reduced amounts of O-fucose to secreted epidermal growth factor-like repeats from NOTCH1 or secr

264 icted to occur at consensus sites within the epidermal growth factor-like repeats in the extracellula

265 e thyrotropin receptor (TSHR) ectodomain and epidermal growth factor-like repeats in the laminin gamm

266 The O-fucose modification is found on epidermal growth factor-like repeats of a number of cell

267 nant protein of domain VI and the first four epidermal growth factor-like repeats of domain V, genera

268 tion between Jagged1 and MAGP-2 requires the epidermal growth factor-like repeats of Jagged1.

269 lcNAcT) that transfers GlcNAc to O-fucose in epidermal growth factor-like repeats of Notch.

270 ain of Cripto-1 and the C-terminal region of epidermal growth factor-like repeats of Notch1.

271 id not exhibit reduced fucosylation of these epidermal growth factor-like repeats or thrombospondin t

272 a recombinant protein consisting of only the epidermal growth factor-like repeats showed no cell bind

273 s delta-like/preadipocyte factor-1, contains epidermal growth factor-like repeats that are related to

274 The Gla domain and epidermal growth factor-like repeats were not required f

275 sites for glycosaminoglycan attachment, two epidermal growth factor-like repeats, a putative hyaluro

276 Its extracellular domain includes epidermal growth factor-like repeats, a von Willebrand f

277 a type-1 membrane protein, 15 extracellular epidermal growth factor-like repeats, and multiple cytop

278 dicted 1713 amino acid protein containing 18 epidermal growth factor-like repeats, four 8-cysteine do

279 The enzyme that adds O-fucose to epidermal growth factor-like repeats, GDP-fucose protein

280 er of cysteine residues in the extracellular epidermal growth factor-like repeats, important for liga

281 , a region related to fibrinogen beta/gamma, epidermal growth factor-like repeats, neurexin motifs as

282 Fibrillins consist of up to 47 epidermal growth factor-like repeats, of which more than

283 act that O-FucT-1 recognizes properly folded epidermal growth factor-like repeats, together with this

284 which is responsible for adding O-fucose to epidermal growth factor-like repeats.

285 omain and an extracellular region containing epidermal growth factor-like repeats.

286 domain V involved the first two laminin- and epidermal growth factor-like repeats.

287 th an extracellular domain that contains ten epidermal growth factor-like repeats.

288 tion of O-linked fucose residues attached to epidermal growth factor-like sequence repeats of Notch.

289 ghlighting the importance of heparin-binding epidermal growth factor-like signaling in blastocyst-ute

290 Neuregulin 4 (NRG4), an epidermal growth factor-like signaling molecule, plays a

291 e leukemia inhibitory factor (LIF) receptor, epidermal growth factor-like transforming growth factor

292 is believed to be mediated by neuregulin, an epidermal growth factor-like trophic factor released by

293 shares a similar organization of Fasciclin, epidermal growth factor-like, Xlink, and transmembrane d

294 binding domains with a laminin alpha 4 chain epidermal-growth-factor-like/ zinc-finger-like motif.